Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
AssigneeThe General Hospital Corporation
InventorsMark C. Poznansky, Patrick Reeves
Life of this patent
Estimating the term…
Abstract
The invention described herein relates to methods and compositions for treating cancer in a patient or a tumor cell by administering an effective amount of an anti-fugetactic agent and an additional anti-cancer agent.
Claims16
A method for killing a human ovarian cancer cell expressing an amount of a chemokine sufficient to produce a fugetactic effect, which method comprises:
- a) periodically contacting said cell with an effective amount of AMD3100 over a period of about 2 days to about 10 days so as to inhibit said fugetactic effect;
- b) contacting said cell with paclitaxel over a period of about 2 days to about 10 days following the period of administering the AMD3100, wherein steps a) and b) are done in sequential order;
- and
- c) optionally repeating steps a) and b) as necessary to kill said human ovarian cancer cell.
A method for treating a solid ovarian tumor in a human which tumor expresses a chemokine at a concentration sufficient to produce a fugetactic effect, which method comprises administering to said human an effective amount of AMD3100 over a period of about 2 days to about 10 days so as to inhibit said fugetactic effect, followed by administering to said human paclitaxel over a period of about 2 days to about 10 days following the period of administering the AMD3100.
Dependencies are inferred from the claim text.